RxDoctor Payments Data

John Russell, DO

Internal Medicine · Kansas City, MONPI 1063486660

Payments from drug & device makers

$991in general payments, 2019–2025

Across 53 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$239
  • Radius Health, Inc.$98
  • Boehringer Ingelheim$90
  • Takeda Pharmaceuticals U.S.A., Inc.$89
  • Amgen$71
  • AstraZeneca$62
  • plus $342 from 14 others

What the payments were for

  • Food & beverage$991100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$991 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$71,805
Medicare patients
289
Services billed
989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$184,499
JardianceEmpagliflozin103$146,770
FarxigaDapagliflozin Propanediol108$98,674
EliquisApixaban97$85,693
XareltoRivaroxaban45$52,835
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$46,425
TrulicityDulaglutide34$44,975
MounjaroTirzepatide34$39,614
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr45$34,578
JanuviaSitagliptin Phosphate17$23,274
EntrestoSacubitril/Valsartan20$22,067
Spiriva HandihalerTiotropium Bromide16$17,548
SymbicortBudesonide/Formoterol Fumarate56$16,104
MyrbetriqMirabegron23$15,184
Omeprazole542$9,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$90$155,727118 claims
AstraZenecaFarxiga, Symbicort$62$114,778164 claims
PfizerEliquis, Premarin, Abrysvo$15$95,782123 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Arnuity Ellipta$13$93,359123 claims
Johnson & JohnsonXarelto$46$52,83545 claims
MerckJanuvia$13$23,27417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →